Dudediligence.

Harrow, Inc

HROWNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$49.3MSep ’24$66.8MDec ’24$47.8MMar ’25$63.7MJun ’25$71.6MSep ’25$89.1MDec ’25$44.2MMar ’26$70.7MJun ’26
Net income, by quarter
−$4.2MSep ’24$6.8MDec ’24−$17.8MMar ’25$5.0MJun ’25$1.0MSep ’25$6.6MDec ’25−$27.6MMar ’26−$17.3MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$72.5M$88.6M$130.2M$199.6M$272.3M
Gross profit$54.3M$63.2M$90.6M$150.4M$204.4M
Operating income$1.6M$1.9M$431,000$8.8M$30.5M
Net income−$18.0M−$14.1M−$24.4M−$17.5M−$5.1M
Operating cash flow$5.1M$1.7M$3.8M−$22.2M$43.9M
Free cash flow$3.3M−$892,000$2.4M−$23.8M$43.0M
Cash$42.2M$96.3M$74.1M$47.2M$72.9M
Debt$103.0M$151.8M$246.7M$262.7M$250.0M
Shares outstanding26.9M29.9M35.2M35.6M37.2M